Information Provided By: 
Fly News Breaks for June 11, 2019
AERI
Jun 11, 2019 | 07:44 EDT
Cantor Fitzgerald analyst Elemer Piros says that with a year's worth of scripts reported for Rhopressa and an early first month look at the Rocklatan launch, he remains confident that Aerie Pharmaceuticals' two drugs are transforming the glaucoma treatment space. With "superior efficacy established" over the number-one prescribed prostaglandin, Aerie's portfolio of glaucoma treatments is best in class, Piros tells investors in a research note. He reiterates an Overweight rating on the shares with an $85 price target.
News For AERI From the Last 2 Days
There are no results for your query AERI
